Loading...
•
Sep 30, 2023
BioCryst Q3 2023 Earnings Report
BioCryst reported Q3 2023 financial results and provided a business update.
Key Takeaways
BioCryst's Q3 2023 revenues reached $86.7 million, driven by ORLADEYO's growth, while R&D expenses decreased and SG&A expenses increased. The company anticipates achieving at least $320 million in ORLADEYO revenue for the full year 2023.
ORLADEYO net revenue for Q3 2023 was $85.7 million, a 29.8 percent increase year-over-year.
The company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue.
Net cash utilization was $16.5 million in Q3 2023, a 43.9 percent decrease year-over-year.
BioCryst will host an R&D Day on November 3rd to introduce additional therapies from its pipeline.
Forward Guidance
BioCryst expects full year 2023 global net ORLADEYO revenue to be no less than $320 million and anticipates operating expenses, excluding non-cash stock compensation, to be between $365 million and $375 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...